Literature DB >> 2160032

Topoisomerases, new targets in cancer chemotherapy.

J G Zijlstra1, S de Jong, E G de Vries, N H Mulder.   

Abstract

The enzymes involved in the regulation of the three-dimensional structure of DNA, topoisomerase I and II, are important for the handling of DNA during vital cellular processes such as translation, transcription and mitosis. The enzymes are currently being studied intensively, they are being biochemically characterized and their mechanism of action is now better understood. Empirically discovered antitumor drugs appear to interfere with these enzymes, especially topoisomerase II. The DNA-topoisomerase II complex, which is an intermediate in the normal enzyme pathway, is stabilized by the drug and forms a 'cleavable complex', which appears to be cytotoxic. The drugs involved are, e.g. anthracyclines, epipodophyllotoxins and acridines. The central role of this enzyme offers the cell an opportunity for the development of resistance by down-regulation of this enzyme or the production of resistant mutants, provided the adaptation does not hamper other vital cell functions. Knowledge of the working mechanism and the cellular regulation of the topoisomerases might lead to the selection of most effective drugs and treatment schedules, and to circumvention of drug resistance.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2160032     DOI: 10.1007/BF03000485

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  106 in total

Review 1.  Recent studies of DNA topoisomerases.

Authors:  J C Wang
Journal:  Biochim Biophys Acta       Date:  1987-06-06

2.  Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes.

Authors:  H Zhang; J C Wang; L F Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

3.  Novel topologically knotted DNA from bacteriophage P4 capsids: studies with DNA topoisomerases.

Authors:  L F Liu; J L Davis; R Calendar
Journal:  Nucleic Acids Res       Date:  1981-08-25       Impact factor: 16.971

4.  Mechanism of inhibition of mammalian DNA topoisomerase I by heparin.

Authors:  K Ishii; S Futaki; H Uchiyama; K Nagasawa; T Andoh
Journal:  Biochem J       Date:  1987-01-01       Impact factor: 3.857

5.  Roles of DNA topoisomerases in simian virus 40 DNA replication in vitro.

Authors:  L Yang; M S Wold; J J Li; T J Kelly; L F Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

6.  In situ localization of DNA topoisomerase II, a major polypeptide component of the Drosophila nuclear matrix fraction.

Authors:  M Berrios; N Osheroff; P A Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

7.  Protein kinase C phosphorylates topoisomerase II: topoisomerase activation and its possible role in phorbol ester-induced differentiation of HL-60 cells.

Authors:  N Sahyoun; M Wolf; J Besterman; T Hsieh; M Sander; H LeVine; K J Chang; P Cuatrecasas
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

8.  Inhibition of epipodophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA cleavage.

Authors:  T Rowe; G Kupfer; W Ross
Journal:  Biochem Pharmacol       Date:  1985-07-15       Impact factor: 5.858

9.  Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino) methanesulfon-m-anisidide and adriamycin.

Authors:  L A Zwelling; S Michaels; L C Erickson; R S Ungerleider; M Nichols; K W Kohn
Journal:  Biochemistry       Date:  1981-11-10       Impact factor: 3.162

10.  Isolation of type I and II DNA topoisomerase mutants from fission yeast: single and double mutants show different phenotypes in cell growth and chromatin organization.

Authors:  T Uemura; M Yanagida
Journal:  EMBO J       Date:  1984-08       Impact factor: 11.598

View more
  6 in total

1.  Which therapy works better in choroid plexus carcinomas?

Authors:  Su G Berrak; Diane D Liu; Brigitte Wrede; Johannes E Wolff
Journal:  J Neurooncol       Date:  2010-10-26       Impact factor: 4.130

2.  Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase II alpha. Delineation of a carboxy-terminal epitope with peptide antibodies.

Authors:  F Boege; A Andersen; S Jensen; R Zeidler; H Kreipe
Journal:  Am J Pathol       Date:  1995-06       Impact factor: 4.307

Review 3.  Topoisomerase I in multiple drug resistance.

Authors:  A Pessina
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

4.  Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance.

Authors:  S de Jong; J G Zijlstra; N H Mulder; E G de Vries
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

5.  Topoisomerase I inhibitors and drug resistance.

Authors:  R E Parchment; A Pessina
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

6.  Evaluation of the Proliferative Activity of Diffuse Large B-Cell Lymphoma (DLBCL) in Dogs with Respect to Patient Eligibility for Anthracycline-Based Chemotherapy.

Authors:  Paweł Klimiuk; Wojciech Łopuszyński; Kamila Bulak; Adam Brzana
Journal:  Animals (Basel)       Date:  2021-04-20       Impact factor: 2.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.